Hepatitis C in North Carolina: Two Epidemics with One Public Health Response



Sarah Rhea, DVM, PhD North Carolina Division of Public Health


State Health Director's Conference
January 21, 2016

Overview

- Review hepatitis C background information
- Describe the epidemiology of hepatitis C
- Discuss public health initiatives to address hepatitis C in NC

Hepatitis C

- Most commonly transmitted through injection drug use
- 75%–85% of infected develop chronic illness



Two epidemics of hepatitis C

Chronic

- Increasing cause of morbidity and mortality
- 75% of cases among "baby boomers"
- 50% unaware of infection



CDC


Acute

- Emerging epidemic
- Young persons who injection drugs
- Coincides with increasing use of injectable opioids



CDC

Reported acute hepatitis C cases, NC, 2000–2014



Characteristic	N (%)
Race/ethnicity White Black Hispanic Other	`
Age (years) <20 21-30 31-40 41-50 >50	7 (6%) 47 (41%) 27 (24%) 21 (19%) 11 (10%)
Gender Male Female Missing	60 (53%) 51 (45%) 2 (2%)
Reported risk factors* Injection drug use Multiple sex partners Men who have sex with men History of blood transfusion Missing	42 (37%) 5 (4%) 2 (2%) 1 (1%) 63 (56%)

^{*}May report >1 risk factor

Characteristic	N (%)
Race/ethnicity White	96 (85%)
Віаск Hispanic Other	3 (4%) 3 (3%) 9 (8%)
Age (years) <20 21-30 31-40 41-50 >50	7 (6%) 47 (41%) 27 (24%) 21 (19%) 11 (10%)
Gender Male Female Missing	60 (53%) 51 (45%) 2 (2%)
Reported risk factors* Injection drug use Multiple sex partners Men who have sex with men History of blood transfusion Missing	42 (37%) 5 (4%) 2 (2%) 1 (1%) 63 (56%)

^{*}May report >1 risk factor

Characteristic	N (%)
Race/ethnicity White Black Hispanic Other	- (
Age (years)	7 (6%)
21-30 31-40	47 (41%)
41-5u >50	21 (19%) 11 (10%)
Gender Male Female Missing	60 (53%) 51 (45%) 2 (2%)
Reported risk factors* Injection drug use Multiple sex partners Men who have sex with men History of blood transfusion Missing	42 (37%) 5 (4%) 2 (2%) 1 (1%) 63 (56%)

^{*}May report >1 risk factor


Characteristic	N (%)
Race/ethnicity White Black Hispanic Other	96 (85%) 5 (4%) 3 (3%) 9 (8%)
Age (years) <20 21-30 31-40 41-50 >50	7 (6%) 47 (41%) 27 (24%) 21 (19%) 11 (10%)
<u>Gender</u> Male	60 (53%)
Female Missing	51 (45%) 2 (2%)
Reported risk factors* Injection drug use Multiple sex partners Men who have sex with men History of blood transfusion Missing	42 (37%) 5 (4%) 2 (2%) 1 (1%) 63 (56%)


^{*}May report >1 risk factor

Characteristic	N (%)
Race/ethnicity White Black Hispanic Other	96 (85%) 5 (4%) 3 (3%) 9 (8%)
Age (years) <20 21-30 31-40 41-50 >50	7 (6%) 47 (41%) 27 (24%) 21 (19%) 11 (10%)
Gender Male Female Missing	60 (53%) 51 (45%) 2 (2%)
Reported risk factors*	40 (070)
Injection drug use	42 (37%)
Multiple Sex partners Men who have sex with men History of blood transfusion Missing	2 (2%) 1 (1%) 63 (56%)

^{*}May report >1 risk factor

Rates of reported acute hepatitis C cases by county, NC, 2014






Counties most vulnerable to a hepatitis C/HIV outbreak

- Data sources
 - Emergency department visits for opioid overdose
 - Reported cases of acute hepatitis C
 - Chronic hepatitis C data from Medicaid
 - Percent white population
 - Percent unemployment
- Identified 11 most vulnerable NC counties, all in western NC

What about chronic hepatitis C in NC?

- Not reportable by law
- Use CDC national prevalence projections (1.1%) and census data to estimate



Changing landscape of hepatitis C treatment

- Older drugs
 - Prolonged treatment
 - Serious side effects
- New direct acting antivirals (DAAs)
 - Shorter treatment
 - Fewer serious side effects
 - Highly effective
 - Expensive
 - Mainly prescribed by specialists

Public health response to hepatitis C in NC

- Enhanced surveillance
 - Chronic hepatitis C reportable through ELR (electronic laboratory reporting)
- Outreach and screening
 - Targeted screening of high risk groups
 - Client education
 - Hepatitis A/B vaccination
- Linkage to cure
 - Hepatitis C Bridge Counselors
 - Expanded primary care capacity to treat HCV